Skip to main content
Top
Published in: Breast Cancer Research 6/2005

Open Access 01-12-2005 | Research article

The estrogen receptor-α A908G (K303R) mutation occurs at a low frequency in invasive breast tumors: results from a population-based study

Authors: Kathleen Conway, Eloise Parrish, Sharon N Edmiston, Dawn Tolbert, Chiu-Kit Tse, Joseph Geradts, Chad A Livasy, Harsharan Singh, Beth Newman, Robert C Millikan

Published in: Breast Cancer Research | Issue 6/2005

Login to get access

Abstract

Introduction

Evidence suggests that alterations in estrogen signaling pathways, including estrogen receptor-α (ER-α), occur during breast cancer development. A point mutation in ER-α (nucleotide A908G), producing an amino acid change from lysine to arginine at codon 303 (K303R) results in receptor hypersensitivity to estrogen. This mutation was initially reported in one-third of hyperplastic benign breast lesions, although several recent studies failed to detect it in benign or malignant breast tissues.

Methods

We screened 653 microdissected, newly diagnosed invasive breast tumors from patients in the Carolina Breast Cancer Study, a population-based case-control study of breast cancer in African American and white women in North Carolina, for the presence of the ER-α A908G mutation by using single-strand conformational polymorphism (SSCP) analysis and 33P-cycle sequencing.

Results

We detected the ER-α A908G mutation in 37 of 653 (5.7%) breast tumors. The absence of this mutation in germline DNA confirmed it to be somatic. Three tumors exhibited only the mutant G base at nucleotide 908 on sequencing, indicating that the wild-type ER-α allele had been lost. The ER-α A908G mutation was found more frequently in higher-grade breast tumors (odds ratio (OR) 2.83; 95% confidence interval (CI) 1.09 to 7.34, grade II compared with grade I), and in mixed lobular/ductal tumors (OR 2.10; 95% CI 0.86 to 5.12) compared with ductal carcinomas, although the latter finding was not statistically significant.

Conclusion

This population-based study, the largest so far to screen for the ER-α A908G mutation in breast cancer, confirms the presence of the mutant in invasive breast tumors. The mutation was associated with higher tumor grade and mixed lobular/ductal breast tumor histology.
Appendix
Available only for authorised users
Literature
1.
go back to reference Pike MC, Spicer DV, Dahmoush L, Press MF: Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev. 1993, 15: 17-35.CrossRefPubMed Pike MC, Spicer DV, Dahmoush L, Press MF: Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev. 1993, 15: 17-35.CrossRefPubMed
2.
go back to reference Murphy LC, Dotzlaw H, Leygue E, Douglas D, Coutts A, Watson PH: Estrogen receptor variants and mutations. J Steroid Biochem Molec Biol. 1997, 62: 363-372. 10.1016/S0960-0760(97)00084-8.CrossRefPubMed Murphy LC, Dotzlaw H, Leygue E, Douglas D, Coutts A, Watson PH: Estrogen receptor variants and mutations. J Steroid Biochem Molec Biol. 1997, 62: 363-372. 10.1016/S0960-0760(97)00084-8.CrossRefPubMed
3.
go back to reference Herynk MH, Fuqua SAW: Estrogen receptor mutations in human disease. Endocr Rev. 2004, 25: 869-898. 10.1210/er.2003-0010.CrossRefPubMed Herynk MH, Fuqua SAW: Estrogen receptor mutations in human disease. Endocr Rev. 2004, 25: 869-898. 10.1210/er.2003-0010.CrossRefPubMed
4.
go back to reference Dotzlaw H, Leygue E, Watson PH, Murphy LC: Expression of estrogen receptor-beta in human breast tumors. J Clin Endocrinol Metab. 1997, 82: 2371-2374. 10.1210/jc.82.7.2371.PubMed Dotzlaw H, Leygue E, Watson PH, Murphy LC: Expression of estrogen receptor-beta in human breast tumors. J Clin Endocrinol Metab. 1997, 82: 2371-2374. 10.1210/jc.82.7.2371.PubMed
5.
go back to reference Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, Nordenskjold M, Gustafsson JA: Human estrogen receptor β-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab. 1997, 82: 4258-4265. 10.1210/jc.82.12.4258.PubMed Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, Nordenskjold M, Gustafsson JA: Human estrogen receptor β-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab. 1997, 82: 4258-4265. 10.1210/jc.82.12.4258.PubMed
6.
go back to reference Hu YF, Lau KM, Ho SM, Russo J: Increased expression of estrogen receptor in chemically transformed human breast epithelial cells. Int J Oncol. 1998, 12: 1225-1228.PubMed Hu YF, Lau KM, Ho SM, Russo J: Increased expression of estrogen receptor in chemically transformed human breast epithelial cells. Int J Oncol. 1998, 12: 1225-1228.PubMed
7.
go back to reference Iwao K, Miyoshi Y, Egawa C, Ikeda N, Noguchi S: Quantitative analysis of estrogen receptor-beta mRNA and its variants in human breast cancer. Int J Cancer. 2000, 88: 733-736. 10.1002/1097-0215(20001201)88:5<733::AID-IJC8>3.0.CO;2-M.CrossRefPubMed Iwao K, Miyoshi Y, Egawa C, Ikeda N, Noguchi S: Quantitative analysis of estrogen receptor-beta mRNA and its variants in human breast cancer. Int J Cancer. 2000, 88: 733-736. 10.1002/1097-0215(20001201)88:5<733::AID-IJC8>3.0.CO;2-M.CrossRefPubMed
8.
go back to reference Henderson BE, Feigelson HS: Hormonal carcinogenesis. Carcinogenesis. 2000, 21: 427-433. 10.1093/carcin/21.3.427.CrossRefPubMed Henderson BE, Feigelson HS: Hormonal carcinogenesis. Carcinogenesis. 2000, 21: 427-433. 10.1093/carcin/21.3.427.CrossRefPubMed
9.
go back to reference Fuqua SAW, Wiltschke C, Zhang QX, Borg A, Castles CG, Friedrichs WE, Hopp T, Hilsenbeck S, Mohsin S, O'Connell P, et al: A hypersensitive estrogen receptor-α mutation in premalignant breast lesions. Cancer Res. 2000, 60: 4026-4029.PubMed Fuqua SAW, Wiltschke C, Zhang QX, Borg A, Castles CG, Friedrichs WE, Hopp T, Hilsenbeck S, Mohsin S, O'Connell P, et al: A hypersensitive estrogen receptor-α mutation in premalignant breast lesions. Cancer Res. 2000, 60: 4026-4029.PubMed
10.
go back to reference Cui Y, Zhang M, Van M, Hopp T, Sukumar S, Fuqua SAW: The K303R ER alpha breast cancer specific mutation resides at a site of coupling ER acetylation and phosphorylation. Proc Am Assoc Cancer Res. 2003, 44: 205- Cui Y, Zhang M, Van M, Hopp T, Sukumar S, Fuqua SAW: The K303R ER alpha breast cancer specific mutation resides at a site of coupling ER acetylation and phosphorylation. Proc Am Assoc Cancer Res. 2003, 44: 205-
11.
go back to reference Zubairy S, Cui Y, Fuqua SA: The K303R estrogen receptor alpha breast cancer mutant generates a new Akt kinase site. Proc Am Assoc Cancer Res. 2004, 45: 659- Zubairy S, Cui Y, Fuqua SA: The K303R estrogen receptor alpha breast cancer mutant generates a new Akt kinase site. Proc Am Assoc Cancer Res. 2004, 45: 659-
12.
go back to reference Cui Y, Zhang M, Pestell R, Curran EM, Welshons WV, Fuqua SAW: Phosphorylation of estrogen receptor α blocks its acetylation and regulates estrogen sensitivity. Cancer Res. 2004, 64: 9199-9208.CrossRefPubMed Cui Y, Zhang M, Pestell R, Curran EM, Welshons WV, Fuqua SAW: Phosphorylation of estrogen receptor α blocks its acetylation and regulates estrogen sensitivity. Cancer Res. 2004, 64: 9199-9208.CrossRefPubMed
13.
go back to reference Newman B, Moorman P, Millikan R, Qaqish BF, Geradts J, Aldrich TE, Liu ET: The Carolina Breast Cancer Study: integrating population-based epidemiology and molecular biology. Breast Cancer Res Treat. 1995, 35: 51-60. 10.1007/BF00694745.CrossRefPubMed Newman B, Moorman P, Millikan R, Qaqish BF, Geradts J, Aldrich TE, Liu ET: The Carolina Breast Cancer Study: integrating population-based epidemiology and molecular biology. Breast Cancer Res Treat. 1995, 35: 51-60. 10.1007/BF00694745.CrossRefPubMed
14.
go back to reference Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PG: Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol. 2000, 151: 703-714.CrossRefPubMed Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PG: Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol. 2000, 151: 703-714.CrossRefPubMed
15.
go back to reference Dressler LG, Geradts J, Burroughs M, Cowan D, Millikan RC, Newman B: Policy guidelines for the utilization of formalin-fixed, paraffin-embedded tissue sections: the UNC SPORE experience. Breast Cancer Res Treat. 1999, 58: 31-39. 10.1023/A:1006354627669.CrossRefPubMed Dressler LG, Geradts J, Burroughs M, Cowan D, Millikan RC, Newman B: Policy guidelines for the utilization of formalin-fixed, paraffin-embedded tissue sections: the UNC SPORE experience. Breast Cancer Res Treat. 1999, 58: 31-39. 10.1023/A:1006354627669.CrossRefPubMed
16.
go back to reference Schubert EL, Lee MK, Newman B, King MC: Single nucleotide polymorphisms (SNPs) in the estrogen receptor gene and breast cancer susceptibility. J Steroid Biochem Molec Biol. 1999, 71: 21-27. 10.1016/S0960-0760(99)00126-0.CrossRefPubMed Schubert EL, Lee MK, Newman B, King MC: Single nucleotide polymorphisms (SNPs) in the estrogen receptor gene and breast cancer susceptibility. J Steroid Biochem Molec Biol. 1999, 71: 21-27. 10.1016/S0960-0760(99)00126-0.CrossRefPubMed
17.
go back to reference Zhang Z, Yamashita H, Toyama T, Omoto Y, Sugiura H, Hara Y, Haruki N, Kobayashi S, Iwase H: Estrogen receptor α mutation (A-to-G transition at nucleotide 908) is not found in different types of breast lesions from Japanese women. Breast Cancer. 2003, 10: 70-73.CrossRefPubMed Zhang Z, Yamashita H, Toyama T, Omoto Y, Sugiura H, Hara Y, Haruki N, Kobayashi S, Iwase H: Estrogen receptor α mutation (A-to-G transition at nucleotide 908) is not found in different types of breast lesions from Japanese women. Breast Cancer. 2003, 10: 70-73.CrossRefPubMed
18.
go back to reference Tokunaga E, Kimura Y, Maehara Y: No hypersensitive estrogen receptor-α mutation (K303R) in Japanese breast carcinomas. Breast Cancer Res Treat. 2004, 84: 289-292. 10.1023/B:BREA.0000019963.67754.93.CrossRefPubMed Tokunaga E, Kimura Y, Maehara Y: No hypersensitive estrogen receptor-α mutation (K303R) in Japanese breast carcinomas. Breast Cancer Res Treat. 2004, 84: 289-292. 10.1023/B:BREA.0000019963.67754.93.CrossRefPubMed
19.
go back to reference Tebbit CL, Bentley RC, Olson JA, Marks JR: Estrogen receptor α (ESR1) mutant A908G is not a common feature in benign and malignant proliferations of the breast. Genes Chromosomes Cancer. 2004, 40: 51-54. 10.1002/gcc.20017.CrossRefPubMed Tebbit CL, Bentley RC, Olson JA, Marks JR: Estrogen receptor α (ESR1) mutant A908G is not a common feature in benign and malignant proliferations of the breast. Genes Chromosomes Cancer. 2004, 40: 51-54. 10.1002/gcc.20017.CrossRefPubMed
20.
go back to reference Davies MPA, O'Neill PA, Innes H, Sibson DR: Hypersensitive K303R oestrogen receptor-α variant not found in invasive carcinomas. Breast Cancer Res. 2004, 7: R113-118. 10.1186/bcr965.CrossRefPubMedPubMedCentral Davies MPA, O'Neill PA, Innes H, Sibson DR: Hypersensitive K303R oestrogen receptor-α variant not found in invasive carcinomas. Breast Cancer Res. 2004, 7: R113-118. 10.1186/bcr965.CrossRefPubMedPubMedCentral
21.
go back to reference Ahrendt SA, Halachmi S, Chow JT, Wu L, Halachmi N, Yang SC, Wehage S, Jen J, Sidransky D: Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. Proc Natl Acad Sci USA. 1999, 96: 7382-7387. 10.1073/pnas.96.13.7382.CrossRefPubMedPubMedCentral Ahrendt SA, Halachmi S, Chow JT, Wu L, Halachmi N, Yang SC, Wehage S, Jen J, Sidransky D: Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. Proc Natl Acad Sci USA. 1999, 96: 7382-7387. 10.1073/pnas.96.13.7382.CrossRefPubMedPubMedCentral
22.
go back to reference Rosenblum BB, Lee LG, Spurgeon SL, Khan SH, Menchen SM, Heiner CR, Chen SM: New dye-labeled terminators for improved DNA sequencing patterns. Nucl Acids Res. 1997, 27: 4500-4504. 10.1093/nar/25.22.4500.CrossRef Rosenblum BB, Lee LG, Spurgeon SL, Khan SH, Menchen SM, Heiner CR, Chen SM: New dye-labeled terminators for improved DNA sequencing patterns. Nucl Acids Res. 1997, 27: 4500-4504. 10.1093/nar/25.22.4500.CrossRef
23.
go back to reference Korch C, Drabkin H: Manganese citrate improves base-calling accuracy in DNA sequencing reactions using rhodamine-based fluorescent dye-terminators. Nucl Acids Res. 1999, 27: 1405-1407. 10.1093/nar/27.5.1405.CrossRefPubMedPubMedCentral Korch C, Drabkin H: Manganese citrate improves base-calling accuracy in DNA sequencing reactions using rhodamine-based fluorescent dye-terminators. Nucl Acids Res. 1999, 27: 1405-1407. 10.1093/nar/27.5.1405.CrossRefPubMedPubMedCentral
24.
go back to reference Michalides R, Griekspoor A, Balkenende A, Verwoerd D, Janssen L, Jalink K, Floore A, Velds A, van 't Veer L, Neefjes J: Tamoxifen resistance by a conformational arrest of the estrogen receptor α after PKA activation in breast cancer. Cancer Cell. 2004, 5: 597-605. 10.1016/j.ccr.2004.05.016.CrossRefPubMed Michalides R, Griekspoor A, Balkenende A, Verwoerd D, Janssen L, Jalink K, Floore A, Velds A, van 't Veer L, Neefjes J: Tamoxifen resistance by a conformational arrest of the estrogen receptor α after PKA activation in breast cancer. Cancer Cell. 2004, 5: 597-605. 10.1016/j.ccr.2004.05.016.CrossRefPubMed
Metadata
Title
The estrogen receptor-α A908G (K303R) mutation occurs at a low frequency in invasive breast tumors: results from a population-based study
Authors
Kathleen Conway
Eloise Parrish
Sharon N Edmiston
Dawn Tolbert
Chiu-Kit Tse
Joseph Geradts
Chad A Livasy
Harsharan Singh
Beth Newman
Robert C Millikan
Publication date
01-12-2005
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 6/2005
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1315

Other articles of this Issue 6/2005

Breast Cancer Research 6/2005 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine